Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Cytosorbents Corp | v331910_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 9, 2013
| CYTOSORBENTS CORPORATION |
| (Exact name of registrant as specified in its charter) |
|
Nevada (State or other jurisdiction of incorporation) |
000-51038 (Commission File Number) |
98-0373793 (IRS Employer Identification No.) |
|
7 Deer Park Drive, Suite K Monmouth Junction, New Jersey (Address of principal executive offices) |
08852 (Zip Code) | |
Registrant’s telephone number, including area code: (732) 329-8885
| N/A |
| (Former name or former address, if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 7.01 | Regulation FD Disclosure. |
Cytosorbents Corporation (the “Company”) issued a letter to its shareholders on January 9, 2013 summarizing the Company’s achievements in 2012 and the Company’s goals for 2013. A copy of the letter is being furnished as Exhibit 99.1 hereto.
The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit Number | Description of Exhibit | |
| 99.1 | “Shareholder letter issued on January 9, 2013” The Shareholder letter is furnished and not filed pursuant to Instruction B.2 of Form 8-K. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CytoSorbents Corporation | ||
| Date: January 11, 2013 | By: |
/s/ Dr. Phillip P. Chan Name: Dr. Phillip P. Chan Title: President and CEO |